ScienceDaily (July 9, 2005) HIV is able to evade the host immune system to cause infection. In particular, HIV downregulates CD4+ immune T cell function, which might aid infection, but the mechanisms underlying this phenomenon are unknown. In a study appearing online on July 7 in advance of print publication of the August 1 issue of the Journal of Clinical Investigation, Yechiel Shai and colleagues from the Weizmann Institute examine the fusion peptide (FP) of HIV.
The researchers show that the FP plays two roles in HIV infection – it works with other domains to mediate fusion of the virus with the cell membrane, while also downregulating the T cell responses that normally would block infection.
The authors show that the HIV FP can co-localize with CD4 and T cell receptor in T cells, and inhibits antigen-specific T cell proliferation. This data highlights a potential immunosuppressive activity specific to HIV infection.
The authors then extend their findings by exploiting the activity of FP and show that it ameliorates the autoimmune disease adjuvant arthritis in rats. This study not only adds to our understanding of the mechanisms of HIV pathogenesis, but it also shows that the FP molecule, independent of HIV, may provide a novel way to decrease undesirable immune responses.
###
Title: HIV-1 Fusion Peptide Targets the TCR and Inhibits Antigen-Specific T-Cell Activation
Recommend this story on Facebook, Twitter,
and Google +1:
Other bookmarking and sharing tools:
Story Source:
The above story is reprinted from materials provided by Journal of Clinical Investigation, via EurekAlert!, a service of AAAS.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Note: If no author is given, the source is cited instead.
Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.
